Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Palm Beach Neurology

Neither a doctor nor a teaching hospital

Research payments

$2,982,968

452 payments

Through program year 2025, Palm Beach Neurology is reported as receiving $2,982,968 in research payments, across 452 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $581,127 151
2024 Research $432,209 70
2023 Research $317,859 55
2022 Research $619,778 52
2021 Research $559,495 79
2020 Research $400,730 36
2019 Research $71,769 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $976,968 127 payments
  2. Biogen, Inc. $574,566 6 payments
  3. Genentech, Inc. $262,978 32 payments
  4. H. Lundbeck A S $171,068 52 payments
  5. Eisai Inc. $169,610 8 payments
  6. ITI, Inc. $160,377 67 payments
  7. Amneal Pharmaceuticals LLC $146,541 20 payments
  8. Teva Pharmaceuticals USA, Inc. $118,320 83 payments
  9. AbbVie, Inc. $83,399 7 payments
  10. Ucb SA $75,265 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $619,114 103 payments
  2. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $345,955 23 payments
  3. Phase II Study for Moderate Ad $262,978 32 payments
  4. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $231,426 1 payment
  5. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $169,610 8 payments
  6. Iti-1284-101 $160,377 67 payments
  7. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $137,216 1 payment
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $130,356 2 payments
  9. A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations $103,649 11 payments
  10. Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments $86,189 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record